
Amgen (AMGN) Stock
Established biotech company selling proven biologic medicines. Here's the price, business snapshot, and what's worth knowing about Amgen in November 2026.
Amgen Inc (AMGN) is a large-cap biotechnology company specialising in human therapeutics, particularly biologic medicines. With a market capitalisation around $162 billion, Amgen generates revenue from established products across oncology, nephrology, inflammation and cardiovascular care, while investing heavily in a diverse R&D pipeline of biologics and novel therapies. The company benefits from recurring revenue from long-tenured biologics, a history of steady free cash flow and a shareholder-friendly dividend policy, but faces typical sector risks: clinical trial setbacks, biosimilar competition, pricing pressure and regulatory scrutiny. Investors should watch product patent expiries, pipeline readouts and any M&A activity. This summary is for educational purposes only and not personalised investment advice; suitability depends on an investor’s goals, timeframe and risk tolerance, and returns are not guaranteed.
Why It’s Moving

Amgen Faces Legal Settlement and Biosimilar Headwinds Despite Strong Guidance
- A proposed settlement has been announced for the class action securities litigation involving shares purchased between July 2020 and April of this year, introducing legal uncertainty.
- Legacy blockbuster drugs Prolia and XGEVA are experiencing significant erosion due to intense biosimilar competition, forcing reliance on newer pipeline assets to maintain growth.
- Despite these headwinds, Amgen has successfully raised its 2026 financial outlook twice, signaling management confidence that newer drugs are effectively offsetting declines in older portfolios.

Amgen Faces Legal Settlement and Biosimilar Headwinds Despite Strong Guidance
- A proposed settlement has been announced for the class action securities litigation involving shares purchased between July 2020 and April of this year, introducing legal uncertainty.
- Legacy blockbuster drugs Prolia and XGEVA are experiencing significant erosion due to intense biosimilar competition, forcing reliance on newer pipeline assets to maintain growth.
- Despite these headwinds, Amgen has successfully raised its 2026 financial outlook twice, signaling management confidence that newer drugs are effectively offsetting declines in older portfolios.
Six-Month Growth Performance
When is the next earnings date for AMGEN INC (AMGN)?
Amgen has not yet confirmed a date for its next earnings report. Based on the company's historical pattern of reporting approximately three months after the previous quarter, the next release is expected around February 2027. This upcoming report will cover results for the fourth quarter of fiscal year 2026.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Amgen's stock as it may not offer significant growth potential right now.
Financial Health
Amgen is performing exceptionally well with strong profits, cash flow, and revenue growth.
Dividend
Amgen's dividend yield of 2.24% provides a modest return for dividend-seeking investors. If you invested $1000 you would be paid $22.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Established Biologics Revenue
Amgen’s marketed biologics provide recurring sales and predictable cash flow, though revenue can be affected by patent loss and biosimilar entrants.
Pipeline & R&D Focus
A deep R&D pipeline drives long-term potential; positive trial results can re-rate the business, while failures can materially affect value.
Global Market Exposure
Amgen sells worldwide, benefiting from geographic diversification, but faces regional pricing and regulatory differences that can influence performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
